NCT03118817View on ClinicalTrials.gov

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 19, 2017

Primary Completion Date

February 4, 2020

Study Completion Date

February 4, 2020

Conditions
Solid Tumor
Interventions
DRUG

HM95573

"Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops"

Trial Locations (7)

13620

Korea, Republic of, Gyeonggi-do, Seongnam-si

28644

Korea, Republic of, Chungcheongbuk-do, Cheongju-si

41404

Korea, Republic of, Gyeongsangbuk-do, Daegu

03722

Korea, Republic of, Seoul, Seoul

05505

Korea, Republic of, Seoul, Seoul

06351

Korea, Republic of, Seoul, Seoul

07061

Korea, Republic of, Seoul, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY